Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.

Area of Science:

• Hematology
• Pharmacology
• Clinical Trials

Background:

• Chronic phase-chronic myeloid leukemia (CP-CML) often requires treatment with tyrosine kinase inhibitors (TKIs).
• Ponatinib is an effective TKI for patients resistant to other TKIs or with the T315I mutation.
• Optimizing ponatinib dosing is crucial for maximizing efficacy while minimizing toxicity.

Purpose of the Study:

• To evaluate the dose-response and exposure-response relationships of ponatinib in CP-CML patients.
• To determine the optimal starting dose and dose reduction strategy for ponatinib in this population.
• To assess the impact of ponatinib exposure on molecular response and safety outcomes.

Main Methods:

• A randomized, phase II dose-optimization trial (OPTIC) involving CP-CML patients.
• Patients were randomized to starting ponatinib doses of 45 mg, 30 mg, or 15 mg daily.
• Markov models and time-to-event models were used to analyze exposure-response and exposure-safety relationships.

Main Results:

• Increased ponatinib exposure correlated with a higher probability of achieving molecular responses (MR1 and MR2).
• Ponatinib exposure was a significant predictor of arterial occlusive events (AOEs) and grade ≥3 thrombocytopenia.
• Simulations predicted higher rates of achieving MR2 at 12 months with a 45-mg starting dose (40.4%) compared to 30 mg (34%) and 15 mg (25.2%).

Conclusions:

• A starting dose of 45 mg ponatinib, with subsequent reduction to 15 mg upon achieving molecular response, is supported by exposure-response analyses.
• This dosing strategy appears to optimize the balance between efficacy and safety in TKI-resistant CP-CML patients.
• The findings provide evidence-based recommendations for ponatinib dosing in specific CP-CML patient populations.